– NeoGenomics wins summary judgment in patent infringement lawsuit against Natera; Court rules Natera’s patents are invalid for claiming ineligible subject matter
– NeoGenomics remains free to make, use, sell, and promote its RaDaR ST molecular residual disease (MRD) assay in the United States
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.